Anish Bhatnagar - 20 Oct 2023 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Chief Executive Officer, Director
Signature
/s/ Anish Bhatnagar
Issuer symbol
SLNO
Transactions as of
20 Oct 2023
Transactions value $
$28,003
Form type
4
Filing time
13 Dec 2023, 21:32:55 UTC
Previous filing
26 May 2023
Next filing
30 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Options Exercise $18,000 +4,000 +2.11% $4.5* 193,283 20 Oct 2023 Direct F1
transaction SLNO Common Stock Options Exercise $3,750 +2,143 +1.11% $1.75* 195,426 20 Oct 2023 Direct F1
transaction SLNO Common Stock Options Exercise $8,750 +3,500 +1.79% $2.5* 198,926 20 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLNO Warrants (right to buy) Options Exercise $0 -4,000 -100% $0* 0 20 Oct 2023 Common Stock 4,000 $4.5 Direct
transaction SLNO Warrants (right to buy) Options Exercise -$948 -2,143 -100% $0.4425 0 20 Oct 2023 Common Stock 2,143 $1.75 Direct F2
transaction SLNO Warrants (right to buy) Options Exercise -$1,548 -3,500 -100% $0.4425 0 20 Oct 2023 Common Stock 3,500 $2.5 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares reported as beneficially owned following the reported transaction is as of October 20, 2023.
F2 The Warrants expire upon the earlier of (i) 30 days following announcement of positive top-line data from the randomized withdrawal period of Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS), or (ii) November 8, 2026.
F3 The Warrants expire upon the earlier of (i) 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS or (ii) November 8, 2026.